SNHG12 and familial pancreatic carcinoma: Consequently, this research elucidated for the first time that SNHG12 is a novel candidate for early diagnosis biomarker and promising treatment target of pancreatic cancer, and SNHG12/miR-320b could be used as alternate therapeutic strategy for better rescuing patients with pancreatic cancer.